VANCOUVER, BRITISH COLUMBIA--(Marketwire - October 02, 2009) - EnWave Corporation (TSX VENTURE: ENW)(FRANKFURT: E4U) (“EnWave”, or the “Company”) has engaged the company SectorSpeak (“the Consultant”) to undertake investor relations and communications activities for the Company in Canada and the U.K. SectorSpeak is a Canadian capital markets consulting company focused on providing investor relations and corporate finance services to North American companies.
John McNicol, President and Co-CEO of EnWave, stated that, “The appointment of SectorSpeak to assist the Company with some of our investor relations activities will provide EnWave with new momentum in shareholder activity. SectorSpeak has a successful track record in supporting companies like ours, and I feel strongly that their skills and industry contacts will benefit EnWave significantly.”
Under the terms of the agreement, EnWave will pay SectorSpeak a monthly retainer fee of $3,000 for its services for a period of 12 months. EnWave will also grant SectorSpeak an option to purchase 200,000 common shares of the company at the price of $0.50 per common share for a period of five years based on the terms and conditions of the Company’s stock option plan, and subject to exchange approval.
SectorSpeak Principal, Mr. Hogan Mullally, will maintain an arms-length relationship with EnWave. Neither Mr. Mullally, nor SectorSpeak, currently holds any shares of EnWave.
About EnWave
Using proprietary technologies developed in conjunction with the University of British Columbia, EnWave is focused on the development of new methods of dehydrating food and biological materials using Radiant Energy Vacuum technology under its nutraREVTM, powderREV, bioREVTM and freezeREV brands. REV technology combines microwave energy transfer under vacuum to dehydrate and alter structures and drive chemical reactions, thereby creating unique product characteristics for both food products and medical applications that include fruit, vegetables, probiotics, enzymes, proteins, food cultures, vaccines and antibodies. More information about EnWave is available at www.enwave.net.
EnWave Corporation
John McNicol, President & Co-CEO
This press release may contain forward-looking information based on management’s expectations, estimates and projections. All statements that address expectations or projections about the future, including statements about the Company’s strategy for growth, product development, market position, expected expenditures and financial results are forward-looking statements. These statements are not a guarantee of future performance and involve a number of risks, uncertainties and assumptions: there is no guarantee that the Company’s REV technology can or will improve dehydration processes in the target industries; even if the Company’s REV technology can be used as described in this document, there is no guarantee that such use will result in orders for the Company’s REV technology.
The TSX Venture Exchange has neither approved nor disapproved the information contained herein. Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.
Contacts:
EnWave Corporation
John McNicol
President & Co-CEO
(604) 601-8524
john.mcnicol@enwave.net
EnWave Corporation
Jennifer Thompson
V.P. Corporate Development & Investor Relations
(604) 603-6549
jthompson@enwave.net
www.enwave.net